Rani Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure ends Dec 17

Rani Therapeutics Holdings, Inc.

Received Nasdaq notice on June 20, 2025 for non-compliance with $1.00 minimum bid price (30 consecutive business days below $1.00).
Must regain compliance by December 17, 2025 by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
If not cured, may transfer to Nasdaq Capital Market for an additional 180-day period, subject to meeting other initial listing standards.
Company will monitor bid price and consider options, including a potential reverse stock split.
No assurance that the company will regain compliance or that Nasdaq will grant an extension.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.